A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis o... von Cupissol, Didier, Seiwert, Tanguy Y., Fayette, Jérôme, Ehrnrooth, Eva, Blackman, Alice Sarah, Cong, Xiuyu Julie, Cohen, Ezra E.W.

Volltext